Attruby’s recent approval positions BBIO as a direct competitor to PFE’s Vyndaqel in ATTR-CM. Attruby has a 42% reduction of heart failure risk with 90% TTR stabilization. So I think it could have a ...
On Friday, the FDA approved BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce ...
BridgeBio's lead drug Attruby's approved for ATTR-CM last November has driven a 40% stock increase; however, competition and market dynamics may limit its near-term revenue potential. Despite ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on September 22, citing the company’s Attruby ...
BridgeBio Pharma’s stock (BBIO) jumped over 16% after the FDA approved its cardiovascular drug, Attruby. This new treatment will compete with Pfizer’s (PFE) Vyndamax, which was extremely popular in ...
BridgeBio Pharma (BBIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings ...
Recent discussions on X about BridgeBio Pharma (BBIO) have centered around the company's strong performance and analyst endorsements. Many users are highlighting the initiation of coverage by major ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best Russell 2000 stocks to buy now. On August 6, TD Cowen reiterated its “Buy” rating on BridgeBio stock and maintained a price target of $60. TD ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best strong buy healthcare stocks to buy now. On July 14, Leerink Partners analyst Mani Foroohar maintained a Buy rating on BridgeBio Pharma, Inc.
Hosted on MSN
Why BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to Analysts
. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...
On 12 February 2026, BridgeBio Pharma reported positive topline Phase 3 PROPEL 3 results for oral infigratinib in children with achondroplasia, showing statistically significant gains in annualized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results